KEY TAKEAWAYS
- The study aimed to investigate the potential of LY9 as a prognostic biomarker and predictor of immunotherapy efficacy in LUAD.
- Researchers hypothesized that LY9 might be a novel prognostic biomarker for LUAD and predict immunotherapy efficacy.
Lymphocyte antigen 9 (LY9) is involved in the development of various tumors and diseases. However, its role in lung adenocarcinoma (LUAD) remains unexplored.
Kun Deng and the team aimed to evaluate the potential of LY9 as a prognostic biomarker and a predictor of immunotherapy efficacy in LUAD.
Researchers analyzed LY9 expression and prognostic value in pan-cancer and LUAD. Correlation analyses were conducted between LY9 expression in LUAD and immune cell infiltration (using the TIMER database and CIBERSORT algorithm), and immune checkpoints (using the GEPIA database).
A potential ceRNA network for LY9 was constructed. LY9-related pathways were explored using Gene Set Enrichment Analysis (GSEA). Validation of differential LY9 mRNA expression was obtained from the GEO database. LUAD tissues were collected for Quantitative Real-time PCR (qRT-PCR) to verify the expression of LY9, CD8, and CD4 and calculate their correlation. Immunohistochemistry (IHC) was performed to verify LY9 protein expression.
Results indicated that LY9 was highly expressed in various tumors, including LUAD. Patients with high LY9 expression had longer overall survival and increased lymphocyte infiltration. LY9 expression in LUAD strongly correlated with immune cell infiltration and immune checkpoints. Functional enrichment analysis revealed LY9’s involvement in multiple immune-related pathways and non-small cell lung cancer.
A ceRNA regulatory network involving LINC00943-hsa-miR-141-3p-LY9 might also be involved. The GSE68465 dataset confirmed differential LY9 mRNA expression in LUAD, and qRT-PCR results showed a strong positive correlation between LY9 and CD4/CD8 T cells. However, IHC failed to detect LY9 protein expression in tumor tissues, and WB experiments validated LY9 protein expression in the OCI-AML-2 cell line.
The study concluded that LY9 mRNA expression is a potential prognostic biomarker for LUAD and could predict immunotherapy response.
Funding support was provided by the Natural Science Foundation of Guangxi Province.
Source: https://pubmed.ncbi.nlm.nih.gov/39193519/
Deng K, Yuan L, Xu Z, et al. (2024). “Study of LY9 as a potential biomarker for prognosis and prediction of immunotherapy efficacy in lung adenocarcinoma.” PeerJ. 2024;12:e17816. Published 2024 Aug 23. doi:10.7717/peerj.17816
